Elekta establishes bond program

STOCKHOLM, March 9 – The Swedish Financial Supervisory Authority (Finansinspektionen) has today approved Elekta’s (EKTA-B.ST) prospectus as part of Elekta’s establishment of a Medium Term Note (MTN) Program, with a limit of SEK 5 billion.

Elekta AB (publ) is the issuer of the MTN Program, which enables issuing of bonds on the Swedish market.

“Effective financing is an important part in the continued implementation of our strategic agenda and continued growth. The bond program gives us a broader opportunity to diversify our funding,” says Håkan Bergström, CFO.

The prospectus is available on Elekta’s website www.elekta.com and will be available at www.finansinspektionen.se.

Elekta has appointed Skandinaviska Enskilda Banken (SEB) as lead manager and SEB, together with Danske Bank, as the issuing agent.

# # #

For further information, please contact:
Håkan Bergström, CFO, Elekta AB
Tel: +46 8 587 25 547, e-mail: hakan.bergstrom@elekta.com         
Time zone: CET: Central European Time

Tobias Bülow, Director Financial Communication, Elekta AB
Tel: +46 722 215 017, e-mail: tobias.bulow@elekta.com
Time zone: CET: Central European Time

The information was published at 16:00 CET on March 9, 2015.

About Elekta
Elekta is a human care company pioneering significant innovations and clinical solutions for treating cancer and brain disorders. The company develops sophisticated, state-of-the-art tools and treatment planning systems for radiation therapy, radiosurgery and brachytherapy, as well as workflow enhancing software systems across the spectrum of cancer care. Stretching the boundaries of science and technology, providing intelligent and resource-efficient solutions that offer confidence to both health care providers and patients, Elekta aims to improve, prolong and even save patient lives.

Today, Elekta solutions in oncology and neurosurgery are used in over 6,000 hospitals worldwide. Elekta employs around 3,800 employees globally. The corporate headquarters is located in Stockholm, Sweden, and the company is listed on NASDAQ Stockholm. Website: www.elekta.com.



About Us

Elekta is proud to be the leading innovator of equipment and software used to improve, prolong and save the lives of people with cancer and brain disorders. Our advanced, effective solutions are created in collaboration with customers, and more than 6,000 hospitals worldwide rely on Elekta technology. Our treatment solutions and oncology informatics portfolios are designed to enhance the delivery of radiation therapy, radiosurgery and brachytherapy, and to drive cost efficiency in clinical workflows. Elekta employs 3,700 people around the world. Headquartered in Stockholm, Sweden, Elekta is listed on NASDAQ Stockholm. www.elekta.com


Documents & Links